FibroBiologics, Historical Cash Flow
| FBLG Stock | 2.84 0.19 7.17% |
Analysis of FibroBiologics, Common cash flow over time is an excellent tool to project FibroBiologics, Common future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 356.4 K or Begin Period Cash Flow of 2.4 M as it is a great indicator of FibroBiologics, Common ability to facilitate future growth, repay debt on time or pay out dividends.
FibroBiologics, |
About FibroBiologics, Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in FibroBiologics, balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which FibroBiologics,'s non-liquid assets can be easily converted into cash.
FibroBiologics, Common Cash Flow Chart
Add Fundamental
Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Most accounts from FibroBiologics, Common's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into FibroBiologics, Common current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
FibroBiologics, Common cash flow statement Correlations
| -0.98 | 0.93 | -1.0 | 1.0 | 0.94 | ||
| -0.98 | -0.97 | 0.98 | -0.98 | -0.9 | ||
| 0.93 | -0.97 | -0.95 | 0.93 | 0.93 | ||
| -1.0 | 0.98 | -0.95 | -1.0 | -0.95 | ||
| 1.0 | -0.98 | 0.93 | -1.0 | 0.94 | ||
| 0.94 | -0.9 | 0.93 | -0.95 | 0.94 |
Click cells to compare fundamentals
FibroBiologics, Common Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
| OEF | iShares SP 100 | |
| GLD | SPDR Gold Shares | |
| OIH | VanEck Oil Services | |
| IBB | iShares Biotechnology ETF | |
| IJH | iShares Core SP |
Additional Information and Resources on Investing in FibroBiologics, Stock
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.62) | Return On Equity (4.34) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.